Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Damora Therapeutics, Inc. (DMRA) · filed Aug 2, 2023

Accession no.
0000947871-23-000809
Filed
Aug 2, 2023, 5:05 PM ET
Trade date
Jul 31, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $628.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 000105595110% Owner
OrbiMed Israel GP II, L.P.CIK 000168209010% Owner
OrbiMed Advisors Israel II LtdCIK 000168209310% Owner
OrbiMed Capital GP VII LLCCIK 000176064810% Owner
OrbiMed Genesis GP LLCCIK 000180874410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 31, 2023Common StockSSaleDisposed−26,622$3.00−$79,866135,531Indirect
Jul 31, 2023Common StockSSaleDisposed−29,700$3.00−$89,100879,867Indirect
Jul 31, 2023Common StockSSaleDisposed−153,078$3.00−$459,2342,105,909Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)